Market Overview of Tasly Pharmaceutical
The shares of Tasly Pharmaceutical Group Co., Ltd. (ticker 600535.SS) closed the trading session on Wednesday, 21 October 2026, unchanged, registering a 0 % fluctuation over the 24‑hour period ending at 12:03 PM Central Europe. The current price on the Shanghai Stock Exchange sits at CNY 13.91 per share, a level that reflects the company’s stable valuation amid recent market volatility.
Trading Volume and Capitalization
In the past day, investors exchanged CNY 202 million worth of Tasly shares, a modest volume relative to the outstanding 1.5 billion shares in circulation. The firm’s market capitalization stands at CNY 20.9 billion, positioning it firmly within the mid‑cap segment of the Shanghai market. Since the close of the previous month, the stock has risen 0.28 %, signalling a subtle yet positive momentum that aligns with the broader trend of pharmaceutical equities.
Technical Indicators
The simple moving average (SMA) over the last 200 days is CNY 14.57, indicating that the current price is trading below its long‑term mean. This suggests a potential oversell or a temporary dip, depending on the broader market context. Over the past 52 weeks, the share price peaked at CNY 16.24 on 20 July 2026 and fell to a low of CNY 12.90 on 29 June 2026. The present price sits roughly midway between these extremes, hinting at a gradual recovery phase.
Comparative Performance with Peer Stocks
| Peer | Recent 24‑Hour Movement | Current Price | Market Capitalization | P/E Ratio |
|---|---|---|---|---|
| Bank of Chongqing –H (1963.HK) | –1.35 % | HKD 8.10 | HKD 29.2 bn | 5.37 |
| Shenzhen Goodix (603160.SS) | 0 % | CNY 52.96 | CNY 24.9 bn | 35.82 |
| Andon Health (002432.SZ) | 0 % | CNY 52.92 | CNY 24.8 bn | 5.11 |
| Atour Lifestyle (ATAT) | +0.94 % | USD 33.35 | USD 3.7 bn | 24.49 |
| China Pharmaceutical (3320.HK) | +1.09 % | HKD 4.53 | HKD 29.2 bn | 6.02 |
While Tasly’s performance remained flat, its peers displayed a mix of modest gains and declines. The pharmaceutical sector, represented here by both domestic and international listings, appears broadly stable, with few outliers in price volatility.
Company Profile
Founded in 2002 and listed on the Shanghai Stock Exchange on 8 August 2002, Tasly Pharmaceutical Group Co., Ltd. is headquartered in Tianjin, China. The company specializes in the development, manufacture, and distribution of a diversified portfolio of healthcare products, including traditional Chinese medicine, biological and chemical medicines. Tasly markets its offerings across the Chinese mainland and maintains an online presence at www.taslyus.com .
Outlook
The flat trading outcome for Tasly in the most recent 24‑hour window suggests that the market is awaiting further catalysts—such as new product approvals, regulatory updates, or macroeconomic signals—to dictate the stock’s trajectory. The company’s solid market cap and steady trading volume provide a foundation for potential upside should favorable news materialize. Investors observing the sector may find value in monitoring the firm’s quarterly earnings releases and any announcements related to its product pipeline.